At Johnson & Johnson, we are proud to provide grants to support educational activities and programs that help healthcare professionals enhance their knowledge as they provide care for their patients.
Requests for educational grants are evaluated consistent with appropriate internal and external guidelines and policies. We prioritize support in areas of scientific interest. Initiatives assisting underrepresented, underserved and/or health disparities are of particular interest to us.
Purpose:
Medical Education Grant funding supports eligible organizations in offering Continuing Medical Education (CME) for Healthcare Professionals (HCPs), including physicians, nurses, residents, and pharmacists by enhancing their skills and knowledge in meeting the needs of patients and the community.
Submission process:
www.cybergrants.com/JJ/grantsandgiving
RFP
Funding decisions:
Following an internal review process, you will be notified of the status of your application within 90 days of a completed submission and no additional information is required.
Delivery Methods:
Delivery methods vary per therapeutic area. They may include live and virtual activities, dinner programs, grand rounds, and on-site engagements with healthcare teams, ensuring our grants reach diverse audiences within the healthcare community.
Areas of Interest:
Neuroscience
Mood - Treatment Resistant Depression - Major Depressive Disorder with inadequate response to 2 or more antidepressants
- Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
- Treatment resistant depression (TRD) in clinical practice: clinical presentation of patients with inadequate response to two oral antidepressants in the same depressive episode
- TRD: early patient identification & treatment initiation
- Primary care provider’s role in the early identification & treatment of TRD
- Collaborative and patient-centric approach for treatment decision making in TRD
- Mechanistic rationale to pharmacological treatment approaches
- Treatment approaches in TRD including interventional treatments
- Early use of newer antidepressants in TRD
- Strategies for preventing relapse in TRD, and the impact of relapse prevention
- Value of innovative treatments from the patient & societal perspective
- Impact MDD & TRD in minoritized communities and populations
Mood – Targeting Novel Pathways in Depression
- Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
- Treatment resistant depression (TRD) in clinical practice: clinical presentation of patients with inadequate response to two oral antidepressants in the same depressive episode
- TRD: early patient identification & treatment initiation
- Primary care provider’s role in the early identification & treatment of TRD
- Collaborative and patient-centric approach for treatment decision making in TRD
- Mechanistic rationale to pharmacological treatment approaches
- Treatment approaches in TRD including interventional treatments
- Early use of newer antidepressants in TRD
- Strategies for preventing relapse in TRD, and the impact of relapse prevention
- Value of innovative treatments from the patient & societal perspective
- Impact MDD & TRD in minoritized communities and populations
- Insomnia as a symptom of MDD
Schizophrenia - Adults with Schizophrenia
- Earlier adoption of long-acting injectable antipsychotics (LAI)
- Clinical stability & persistency through advancing patients to a longer dosing interval
- Switching oral antipsychotics to long-acting injectable antipsychotics
- Schizophrenia and life expectancy
- Effects and dynamics of a therapeutic alliance between the treatment team (incl nurse practitioners & pharmacists) and patient/caregiver to co-create a treatment plan early in the patient journey helping patients progress through their treatment plan
- Patient & caregiver preferences in LAI utilization
- Patterns of antipsychotic LAI utilization in minoritized communities and populations (including social determinants of health)
- Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
- Antipsychotic LAI transition of care models (inpatient to outpatient)
- Champion the destigmatization of schizophrenia to encourage compassion and acceptance
Pulmonary Hypertension
Continuing Medical Education (Pulmonologists, Cardiologists, RPh, NPs/PAs, PCPs, Rheums )
- Early diagnosis
- Combination therapy
- Risk assessment
- Managing side effects
- Titration
- Shared decision making and care path communication with patients, families, and clinicians
- Meth associated pulmonary arterial hypertension
- Pulmonary arterial hypertension and connective tissue disease
- Pulmonary arterial hypertension – imaging through Echocardiography
Patient Education
- Risk/Benefit with treatment
- Impact of disease progression
- Disease state
- Pregnancy/Safety
Fellowships
- Will consider requests from top academic institutions
Oncology
Multiple Myeloma
Newly Diagnosed
- Transplant eligible/ineligible NDMM
- Maintenance therapy
- Understanding the role of MRD in defining or adapting duration of therapy
- High Risk patients, including elderly and minority patients
- Defining roles of Triplet & Quad based therapy
Relapsed Refractory
- MOA and clinical use of BCMA & GPRC5D targeting bispecific antibodies (BsAbs)
- Novel combinations of bispecific antibodies
- Bridging therapy for CAR-T
- Sequencing of BCMA and GPRC5D, and of bispecifics and CAR-T
- Optimal therapy for patient groups (high risk, elderly, etc)
- Integration of BsAbs into practice
- RWE
- In patient/out-patient strategies for step up dosing
- Patient selection
- AE mitigation and management
- On target off tumor AE’s
- Care Coordination (Academic/Community HCPs)
- Outpatient Administration & Remote Monitoring
Solid Tumor
Non-small cell lung cancer
Bladder Cancer
Prostate Cancer
Immunology/Autoantibody
Immunology Areas of Interest:
Gastroenterology
- Crohn’s Disease
- Ulcerative Colitis
Dermatology
- Plaque Psoriasis
Rheumatology
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Polyarticular Juvenile Idiopathic Arthritis
Autoantibody
- Generalized Myasthenia Gravis
- wAIHA- Warm Autoimmune Hemolytic Anemia